Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 7/20 | 0.41 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 2/20 | 0.36 |
| ▸ | CTSK | P43235 | 2/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13397115 | 0.87 | CA1 (0.35) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL16124756 | 0.83 | MAPT (0.41) | CTSK | |
| SCHEMBL7863783 | 0.83 | AAK1 (0.48) | AAK1CAPN1CA1CA2CA7 | |
| SCHEMBL13397796 | 0.83 | PLA2G2A (0.33) | CA1CA2CA7CTSK | |
| SCHEMBL3305639 | 0.82 | AAK1 (0.48) | AAK1CAPN1CA1CA2CA7 | |
| SCHEMBL3307614 | 0.82 | AAK1 (0.46) | AAK1CAPN1CA1CA2CA7 | |
| SCHEMBL16124691 | 0.82 | CAPN1 (0.46) | AAK1CAPN1CA1CA2CA7 | |
| SCHEMBL13416354 | 0.82 | AAK1 (0.42) | AAK1CAPN1CA1CA2CA7 | |
| SCHEMBL3310054 | 0.81 | ATM (0.51) | CTSLCTSKCTSBCTSS | |
| SCHEMBL3310047 | 0.81 | ATM (0.51) | CTSLCTSKCTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9266820-B2 | Nitric oxide donor compounds | NICOX SCIENCE IRELAND (IE) | 2016-02-23 | — | — | US | disclosed |
| US-9266820-B2 | Nitric oxide donor compounds | NICOX SCIENCE IRELAND (IE) | 2016-02-23 | — | — | US | disclosed |
| US-20140288142-A1 | NITRIC OXIDE DONOR COMPOUNDS | NICOX SA (FR) | 2014-09-25 | — | — | US | disclosed |
| US-20140288142-A1 | NITRIC OXIDE DONOR COMPOUNDS | NICOX SA (FR) | 2014-09-25 | — | — | US | disclosed |
| US-20100099729-A1 | NITRIC OXIDE DONOR COMPOUNDS | NICOX S.A. (FR) | 2010-04-22 | — | — | US | disclosed |
| US-20100099729-A1 | NITRIC OXIDE DONOR COMPOUNDS | NICOX S.A. (FR) | 2010-04-22 | — | — | US | disclosed |
| EP-2125695-A2 | NITRIC OXIDE DONOR COMPOUNDS | Nicox S.A. (FR) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008095841-A2 | NITRIC OXIDE DONOR COMPOUNDS | NICOX S.A. (FR) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288142-A1 | NITRIC OXIDE DONOR COMPOUNDS | NOS3, NOS2, NOS1 | AAK1 3632/4885CAPN1 3307/4885CA1 4365/4885 |
| US-20100099729-A1 | NITRIC OXIDE DONOR COMPOUNDS | NOS3, NOS2, NOS1 | AAK1 3349/4885CAPN1 3378/4885CA1 4414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.